Armodafinil vs Sabroxy (Oroxylum indicum)

Mechanism

The isolated R-enantiomer of racemic modafinil, sharing the same primary mechanism — selective inhibition of the dopamine transporter (DAT) — but with distinct pharmacokinetics. The R-enantiomer has a terminal half-life of ~15 hours vs. ~4-5 hours for the S-enantiomer, resulting in 33-40% higher plasma AUC compared to equimolar racemic modafinil. This translates to more sustained wakefulness-promoting activity throughout the day. Same downstream activation of orexinergic, histaminergic, and noradrenergic pathways as modafinil.

Standard Dosing

75-150 mg once daily (for educational context only — prescription medication in most jurisdictions)

Timing

Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours.

Cycle Duration

Same as modafinil; not typically cycled in clinical use.

Side Effects

• Headache
• Nausea
• Dizziness
• Insomnia (more pronounced than modafinil due to longer half-life)
• Anxiety
• Dry mouth
• Diarrhea
• Stevens-Johnson syndrome (very rare)

Contraindications

• Same as modafinil: mitral valve prolapse, left ventricular hypertrophy, severe hepatic impairment, severe anxiety/psychotic disorders, hypersensitivity, pregnancy

Best Stacking Partners

Mechanism

Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.

Contraindications

• Concurrent MAO inhibitors